Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. It is used to treat certain types of cancer by targeting and inhibiting cancer cell growth [1].
How does Onivyde work to treat cancer?
Onivyde works by delivering irinotecan directly to cancer cells within a lipid bilayer. This liposomal encapsulation is designed to prolong the circulation of irinotecan in the body and improve its delivery to tumor sites. Once delivered, irinotecan interferes with DNA replication in rapidly dividing cancer cells, leading to cell death [1].
What specific cancers is Onivyde approved for?
Onivyde is indicated for the treatment of adult patients with a rare form of pancreatic cancer called pancreatic adenocarcinoma [1]. It is specifically used in combination with other chemotherapy agents for patients whose disease has progressed after first-line chemotherapy [1].
What is the difference between Onivyde and other irinotecan treatments?
The primary difference lies in the formulation. Onivyde is a liposomal formulation, meaning the irinotecan is enclosed in tiny fat-like bubbles (liposomes). This differs from standard irinotecan, which is not encapsulated. The liposomal delivery system aims to alter the pharmacokinetic profile of irinotecan, potentially leading to different efficacy and toxicity profiles [1].
When might Onivyde patents expire?
Patent expiry dates are critical for understanding when generic versions of a drug might become available. Information regarding specific patent expiry dates for Onivyde can be found on specialized databases [2]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would be a resource for this type of inquiry [2].
What are the common side effects of Onivyde?
Patients treated with Onivyde, in combination with other chemotherapies, commonly experience side effects such as diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis (mouth sores) [1]. It is important for patients to discuss any side effects with their healthcare provider, as management strategies are available [1].
Are there clinical trials investigating Onivyde for other uses?
Ongoing clinical trials explore the potential of Onivyde in other cancer types and treatment settings. Research aims to determine if its unique delivery mechanism offers benefits in different malignancies or as a part of novel treatment combinations [1].
Sources:
[1] https://www.onivyde.com/
[2] https://drugpatentwatch.com/